Belluscura was established in the U.K. as a medical device company focused on developing oxygen enrichment technology to help improve health for Chronic Obstructive Pulmonary Disease (COPD) patients and more favorable economic outcomes for the patient, provider, and insurance companies. COPD is the third leading cause of death in the United States, affecting approximately 30 million people in the U.S. and over 100 million worldwide. Belluscura, now with North American headquarters located in Texas, is dedicated to developing proprietary, patented oxygen enrichment technologies that can be applied across a range of treatment possibilities and positively impact millions of people across the globe.